Mostrar el registro sencillo del ítem

dc.creatorSiokas V., Kardaras D., Aloizou A.-M., Liampas I., Papageorgiou E., Drakoulis N., Tsatsakis A., Mitsias P.D., Hadjigeorgiou G.M., Tsironi E.E., Dardiotis E.en
dc.date.accessioned2023-01-31T09:56:56Z
dc.date.available2023-01-31T09:56:56Z
dc.date.issued2020
dc.identifier10.1007/s12031-020-01553-4
dc.identifier.issn08958696
dc.identifier.urihttp://hdl.handle.net/11615/79038
dc.description.abstractBlepharospasm (BSP) is a neurological movement disorder. Coffee consumption has been found to have a protective effect against BSP. BSP and apraxia of eyelid opening are particularly common among patients with PD. The CYP1A2 rs762551 and ADORA2A rs5760423 variants have been previously marginally associated with the risk of PD and are also implicated in caffeine metabolism pathways. The aim of the present study was to evaluate the effect of the CYP1A2 rs762551 and ADORA2A rs5760423 variants on BSP. A Southeastern European Caucasian (SEC) cohort of 206 BSP patients and 206 healthy controls was genotyped for rs762551 and rs5760423. CYP1A2 rs762551 was associated with a decreased BSP risk in the dominant (OR (95% CI) 0.62 (0.41–0.92), p = 0.017), log-additive (OR (95% CI) 0.68 (0.51–0.92), p = 0.011), and co-dominant modes (for the CC genotype OR (95% CI) 0.49 (0.25–0.93), p = 0.038). We provide preliminary evidence that CYP1A2 rs762551 is associated with BSP. Further studies and replication of our results are needed. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.en
dc.language.isoenen
dc.sourceJournal of Molecular Neuroscienceen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85085556443&doi=10.1007%2fs12031-020-01553-4&partnerID=40&md5=3a0b6922641a05131363f072b1bb8c56
dc.subjectadenosine receptoren
dc.subjectadenosine receptor subtype A2aen
dc.subjectcaffeineen
dc.subjectcytochrome P450 1A2en
dc.subjectunclassified drugen
dc.subjectadenosine A2a receptoren
dc.subjectADORA2A protein, humanen
dc.subjectCYP1A2 protein, humanen
dc.subjectcytochrome P450 1A2en
dc.subjectageden
dc.subjectArticleen
dc.subjectblepharospasmen
dc.subjectclinical examinationen
dc.subjectcohort analysisen
dc.subjectcontrolled studyen
dc.subjectDNA isolationen
dc.subjectfemaleen
dc.subjectgenetic polymorphismen
dc.subjectgenetic susceptibilityen
dc.subjectgenetic variabilityen
dc.subjectgenotypeen
dc.subjecthumanen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectonset ageen
dc.subjectParkinson diseaseen
dc.subjectsingle nucleotide polymorphismen
dc.subjectblepharospasmen
dc.subjectgeneticsen
dc.subjectmiddle ageden
dc.subjectsingle nucleotide polymorphismen
dc.subjectAgeden
dc.subjectBlepharospasmen
dc.subjectCytochrome P-450 CYP1A2en
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPolymorphism, Single Nucleotideen
dc.subjectReceptor, Adenosine A2Aen
dc.subjectHumana Press Inc.en
dc.titleCYP1A2 rs762551 and ADORA2A rs5760423 Polymorphisms in Patients with Blepharospasmen
dc.typejournalArticleen


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem